SCHEMBL30134026

SCHEMBL30134026

CC(=O)c1ccc2nc(C)cnc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.46
CYP2A6 P11509 1/20 0.43
MAP4K4 O95819 1/20 0.43
CSNK1G2 P78368 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
MAP4K5 Q9Y4K4 1/20 0.43
SLC2A1 P11166 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
NPC1 O15118 5/20 0.41
RAB9A P51151 3/20 0.41
MAPT P10636 5/20 0.41
ALDH1A1 P00352 4/20 0.41
HPGD P15428 2/20 0.41
GUSB P08236 1/20 0.40
FGFR1 P11362 1/20 0.40
KDM4E B2RXH2 2/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22237575 0.93 TDP1 (0.46) TDP1CYP2A6MAP4K4CSNK1G2CLK4
SCHEMBL29985396 0.86 TDP1 (0.64) TDP1HTTNPC1RAB9AMAPT
SCHEMBL2629411 0.86 TDP1 (0.64) TDP1HTTNPC1RAB9AMAPT
SCHEMBL14741522 0.85 KMT2A (0.46) TDP1NPC1RAB9AMAPTHPGD
SCHEMBL18995952 0.83 MAP4K4 (0.43) TDP1CYP2A6MAP4K4CSNK1G2CLK4
SCHEMBL30899969 0.82 MAP4K4 (0.40) TDP1CYP2A6MAP4K4CSNK1G2CLK4
SCHEMBL30134167 0.82 MAP4K4 (0.40) TDP1CYP2A6MAP4K4CSNK1G2CLK4
SCHEMBL10151651 0.81 MAP4K4 (0.42) TDP1CYP2A6MAP4K4CSNK1G2CLK4
SCHEMBL25527753 0.81 ALDH1A1 (0.49) TDP1CYP2A6MAP4K4CSNK1G2CLK4
SCHEMBL2629412 0.79 TDP1 (0.64) TDP1HTTNPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119119033-A Pyrazolopyridone compounds 百济神州有限公司 2024-12-13 CN disclosed
US-20240300951-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-09-12 US disclosed
US-20240270751-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-08-15 US disclosed
EP-4380936-A1 PYRAZOLOPYRIDINONE COMPOUNDS BeiGene, Ltd. (KY) 2024-06-12 EP disclosed
CN-117836296-A Pyrazolopyridone compounds 百济神州有限公司 2024-04-05 CN disclosed
WO-2023011456-A1 PYRAZOLOPYRIDINONE COMPOUNDS BEIGENE, LTD. (KY) 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300951-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK TDP1 959/4885CYP2A6 3696/4885MAP4K4 584/4885
US-20240270751-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK TDP1 959/4885CYP2A6 3696/4885MAP4K4 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.